| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
| Targets |
Myelin oligodendrocyte glycoprotein peptide (35-55), mouse, rat (MOG (35-55); 0-50 μg/mL; 72 hours; lymph node cells) promotes T cell proliferation and secretion of Th1 cells factors, including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. Myelin oligodendrocyte glycoprotein peptide (35-55) raises IgG levels in mice and rats [1].
|
|---|---|
| ln Vitro |
Myelin oligodendrocyte glycoprotein peptide (35-55), mouse, rat (MOG (35-55); 0-50 μg/mL; 72 hours; lymph node cells) promotes T cell proliferation and secretion of Th1 cells factors, including IFN-γ, TNF-α, IL-10, IL-4 and IL-5. Myelin oligodendrocyte glycoprotein peptide (35-55) raises IgG levels in mice and rats [1].
In a competitive peptide binding ELISA, mouse MOG-35–55 peptide bound to recombinant HLA-DR2-derived molecules with an EC50 of 1.6 µM, indicating higher binding affinity compared to the human variant (EC50 = 13.5 µM). [1] Lymph node T cells from HLA-DR2+ transgenic mice immunized with mouse MOG-35–55 exhibited strong proliferation in response to the peptide in a dose-dependent manner (tested at 50, 10, and 2 µg/mL). [1] Cultured lymph node cells from immunized mice secreted high levels of Th1 cytokines (IFN-γ and TNF-α) upon stimulation with mouse MOG-35–55 peptide, with low baseline levels of IL-10, IL-4, and IL-5. [1] Serum from mice immunized with mouse MOG-35–55 contained high levels of IgG antibodies reactive to both the mouse and human MOG-35–55 peptides. [1] |
| ln Vivo |
Models of mouse cerebral ischemia can be created using rats, mice, and myelin oligodendrocyte glycoprotein peptide (35–55).
Immunization of HLA-DR2 (DRB11501) transgenic mice with mouse MOG-35–55 peptide (200 µg in CFA, plus pertussis toxin) induced severe chronic experimental autoimmune encephalomyelitis (EAE) in 20 out of 21 mice (95% incidence). The mean disease onset was day 10 post-immunization, with a mean peak clinical score of 4.8 (scale 0-6) and an average daily score of 3.4. The disease was chronic and progressive, characterized by ascending paralysis. [1] Histopathological analysis of spinal cords from affected mice showed profuse perivascular inflammatory lesions and possible demyelination. [1] The peptide failed to induce clinical or histological EAE in HLA-DR2-negative littermates lacking both DR2 and mouse MHC class II expression. [1] |
| Cell Assay |
Lymphocyte Proliferation Assay: Draining lymph node cells (4 × 10⁵ cells/well) from immunized mice were cultured in 96-well plates for 72 hours in the presence or absence of mouse MOG-35–55 peptide (at 50, 10, or 2 µg/mL). During the last 18 hours of culture, 0.5 µCi/well of [³H]thymidine was added. Cells were harvested, and thymidine uptake was measured using a liquid scintillation counter. [1]
Cytokine Detection (Cytometric Bead Array): Supernatants from the 72-hour lymphocyte cultures were collected. Levels of TNF-α, IFN-γ, IL-2, IL-4, and IL-5 were simultaneously quantified using a commercial cytometric bead array kit. Beads, supernatant, and detection reagent were incubated for 2 hours at room temperature in the dark, washed, and analyzed by flow cytometry. Cytokine concentrations (pg/mL) were determined using standard curves. [1] IL-10 ELISA: Cell culture supernatants were evaluated for IL-10 using a commercial ELISA kit. Plates were read on a microplate reader, and concentrations were quantified against a standard curve. [1] |
| Animal Protocol |
Animal/Disease Models: HLA-DR2 (DRB1*1501) mice [1]
Doses: 200 μg (0.2 mL) Route of Administration: intraperitoneal (ip) injection; once for 38 days Experimental Results: Causes paralysis of hind limbs and forelimbs. Induction of Active EAE: HLA-DR2 transgenic mice (8-12 weeks old) were immunized subcutaneously at four sites on the flanks with a total of 0.2 mL of an emulsion. The emulsion contained 200 µg of mouse MOG-35–55 peptide in Complete Freund's Adjuvant (CFA) supplemented with 400 µg of heat-killed Mycobacterium tuberculosis H37RA. On the day of immunization (day 0) and two days later (day 2), mice received intraperitoneal injections of pertussis toxin (25 ng and 67 ng per mouse, respectively). [1] Mice were monitored daily for clinical signs of EAE and scored on a scale from 0 (normal) to 6 (moribund/paraplegia with severe forelimb weakness). [1] |
| References |
|
| Additional Infomation |
The mouse MOG-35-55 peptide (sequence: MEVGWYRSPFSRVHLYRNGK) is a myelin-derived peptide used to induce experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). [1] Its encephaloinflammatory activity is restricted by the human MHC class II allele HLA-DR2 (DRB11501), which is associated with increased susceptibility to MS. [1] The difference in amino acid position 42 between the mouse and human MOG-35-55 peptides (serine in mice, proline in humans) results in significantly higher encephaloinflammatory activity and HLA-DR2 binding affinity of the mouse MOG-35-55 peptide compared to the human MOG-35-55 peptide. [1] This peptide model, constructed in HLA-DR2 transgenic mice, is considered a useful tool for testing novel therapies targeting human MHC class II molecules and antigen-specific T-cell receptors. [1]
|
| Molecular Formula |
C118H177N35O29S
|
|---|---|
| Molecular Weight |
2581.9501
|
| Exact Mass |
2580.317
|
| CAS # |
149635-73-4
|
| Related CAS # |
Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat TFA;Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat acetate
|
| PubChem CID |
17838836
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Index of Refraction |
1.678
|
| LogP |
-1.49
|
| Hydrogen Bond Donor Count |
39
|
| Hydrogen Bond Acceptor Count |
36
|
| Rotatable Bond Count |
84
|
| Heavy Atom Count |
183
|
| Complexity |
5670
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C([H])([H])[H])C([H])([H])C([H])([H])C([H])(C(N([H])C([H])(C([H])([H])C([H])([H])C(=O)O[H])C(N([H])C([H])(C([H])(C([H])([H])[H])C([H])([H])[H])C(N([H])C([H])([H])C(N([H])C([H])(C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)C(N([H])C([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])C(N([H])C([H])(C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])C(N([H])C([H])(C([H])([H])O[H])C(N1C([H])([H])C([H])([H])C([H])([H])C1([H])C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])([H])C(N([H])C([H])(C(=O)O[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N\[H])/N([H])[H])=O)C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C1=C([H])N([H])C([H])=N1)=O)C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N\[H])/N([H])[H])=O)C([H])([H])O[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)N([H])[H]
|
| InChi Key |
JMTCEFUSRHYJBF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C118H177N35O29S/c1-61(2)47-80(103(169)143-81(49-66-30-34-70(156)35-31-66)104(170)139-75(26-17-42-129-116(122)123)99(165)145-86(53-90(121)158)98(164)133-56-91(159)136-79(115(181)182)25-15-16-41-119)142-108(174)85(52-69-55-128-60-135-69)147-112(178)95(63(5)6)152-113(179)96(64(7)8)151-101(167)77(28-19-44-131-118(126)127)141-109(175)87(58-154)148-106(172)83(48-65-21-11-10-12-22-65)146-110(176)89-29-20-45-153(89)114(180)88(59-155)149-100(166)76(27-18-43-130-117(124)125)140-105(171)82(50-67-32-36-71(157)37-33-67)144-107(173)84(51-68-54-132-74-24-14-13-23-72(68)74)137-92(160)57-134-111(177)94(62(3)4)150-102(168)78(38-39-93(161)162)138-97(163)73(120)40-46-183-9/h10-14,21-24,30-37,54-55,60-64,73,75-89,94-96,132,154-157H,15-20,25-29,38-53,56-59,119-120H2,1-9H3,(H2,121,158)(H,128,135)(H,133,164)(H,134,177)(H,136,159)(H,137,160)(H,138,163)(H,139,170)(H,140,171)(H,141,175)(H,142,174)(H,143,169)(H,144,173)(H,145,165)(H,146,176)(H,147,178)(H,148,172)(H,149,166)(H,150,168)(H,151,167)(H,152,179)(H,161,162)(H,181,182)(H4,122,123,129)(H4,124,125,130)(H4,126,127,131)
|
| Chemical Name |
6-amino-2-[[2-[[4-amino-2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[(2-amino-4-methylsulfanylbutanoyl)amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoyl]amino]acetyl]amino]hexanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3873 mL | 1.9365 mL | 3.8730 mL | |
| 5 mM | 0.0775 mL | 0.3873 mL | 0.7746 mL | |
| 10 mM | 0.0387 mL | 0.1937 mL | 0.3873 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
